Advances of Antimicrobial Peptides in the Treatment of Multidrug-Resistant Bacteria
BioDrugs · 2025-11 · 39 (6) · 899-922
DOI: 10.1007/s40259-025-00740-2 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift BioDrugs, online erschienen am 02.10.2025. Verfasst von Yuanzhi Ju und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Pharmacy, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, 310003, Zhejiang, China. Hauptthemen laut MEDLINE: Antimicrobial Peptides, Bacteria, Drug Resistance, Multiple, Bacterial. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 136 Literaturangaben. Gefördert von: Interdisciplinary Research Project of Hangzhou Normal University, National Natural Science and Foundation of China, Jiangxi Provincial Natural Science Foundation.
Abstract (Originalsprache)
Drug-resistant bacteria have become one of the greatest threats to human health in recent decades. With the large-scale abuse of antibiotics, bacteria resistant to traditional antibiotics are becoming increasingly common while clinical options for treating refractory infections are rapidly diminishing. Antimicrobial peptides (AMPs) as a promising alternative to traditional antibiotics, exhibit unique antibacterial mechanisms and potent antimicrobial activity. In recent years, numerous AMPs have been identified and validated in laboratory settings for their efficacy against the 'ESKAPE' pathogens, including Enterococcus faecium, Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa, and Enterobacter species. Although the clinical translation of AMPs is currently hindered by challenges such as stability, toxicity, and production costs, advances in biotechnology and continued research are paving the way for their development as promising alternatives for treating drug-resistant ESKAPE pathogens. This review focuses on summarizing AMPs with demonstrated efficacy against ESKAPE pathogens and explores their clinical application potential, aiming to provide insights for future AMP research and therapeutic development.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Clinical Pharmacy, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, 310003, Zhejiang, China.
- Research Center for Clinical Pharmacy, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou, 310058, Zhejiang, China.
- Department of Stomatology, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, 310003, Zhejiang, China.
- School of Pharmacy, Hangzhou Normal University, Hangzhou, 311121, Zhejiang, China.
- School of Pharmacy, Hangzhou Normal University, Hangzhou, 311121, Zhejiang, China. shen.jiawei@hotmail.com.
- Key Laboratory of Element Class Anti-Cancer Chinese Medicines; Engineering Laboratory of Development and Application of Traditional Chinese Medicines, Collaborative Innovation Center of Traditional Chinese Medicines of…
Förderung
- Interdisciplinary Research Project of Hangzhou Normal University
- National Natural Science and Foundation of China
- Jiangxi Provincial Natural Science Foundation
- Zhejiang Provincial Natural Science Foundation of China
- Pioneer and Leading Goose R&D Program of Zhejiang
Zitieren
APA
Ju, Y., Weng, L., Lin, T., Yang, X., Song, J., Wang, J., Su, H., Chen, P., Shuai, W., Shen, J. W., Du, Y., & Jiang, S. (2025). Advances of Antimicrobial Peptides in the Treatment of Multidrug-Resistant Bacteria. BioDrugs, 39(6), 899-922. https://doi.org/10.1007/s40259-025-00740-2
Vancouver
Ju Y, Weng L, Lin T, Yang X, Song J, Wang J, et al. Advances of Antimicrobial Peptides in the Treatment of Multidrug-Resistant Bacteria. BioDrugs. 2025;39(6):899-922. doi:10.1007/s40259-025-00740-2
BibTeX
@article{Ju2025,
author = {Ju, Yuanzhi and Weng, Luxi and Lin, Tiantian and Yang, Xiaohui and Song, Jiasheng and Wang, Jingxiang and Su, Huimin and Chen, Pengqin and Shuai, Wuping and Shen, Jia-Wei and Du, Yongzhong and Jiang, Saiping},
title = {Advances of Antimicrobial Peptides in the Treatment of Multidrug-Resistant Bacteria},
journal = {BioDrugs},
year = {2025},
volume = {39},
number = {6},
pages = {899--922},
doi = {10.1007/s40259-025-00740-2}
}
EUVIMED